In 2025, a story emerged showcasing real clinical breakthroughs in AI-suggested drug repurposing. It follows the process of applying the existing drug dupilumab to a patient with food protein-induced enterocolitis syndrome (FPIES), and how AI independently proposed this treatment -- suggesting the potential for future medical innovation. This article vividly traces the actual clinical experience, the AI's suggestion process, and the future research directions.
1. The Problem and the Patient
The story begins with Dr. Derya Unutmaz introducing GPT-5 Pro's remarkable treatment suggestion. The key point is that AI independently proposed a new treatment for a patient with FPIES, a rare food allergy caused by specific food proteins.
Dr. Oral Alpan, a close friend of Dr. Unutmaz and a physician-scientist, was treating a patient who had been struggling with treatment. The patient suffered from allergic skin disease and began treatment with dupilumab, a conventionally approved biologic agent for skin conditions.
However, this patient also had FPIES, a food allergy where even small amounts of wheat triggered severe abdominal pain, watery diarrhea, and sometimes bloody stools within hours.
"There is no approved treatment for FPIES. Patients are advised to avoid trigger foods and prepare emergency measures in case of accidental ingestion."
The patient had suffered from these symptoms for 20 years, with even small amounts of wheat triggering symptoms within hours.
2. An Unexpected Trip, a New Clue
After starting dupilumab treatment, the patient happened to eat a baguette (a wheat product) while traveling in France. Remarkably, no reaction occurred, unlike before. It was the first symptom-free wheat consumption in 20 years.
"For the first time in 20 years, he experienced wheat consumption with no symptoms whatsoever!"
After returning to the United States, Dr. Alpan suspected that dupilumab might be the cause of the change and conducted a supervised oral challenge test with 50 grams of wheat protein. Once again, no symptoms appeared.
When the patient later had to temporarily stop the medication due to insurance issues, the previous symptoms returned. When treatment resumed, tolerance was restored.
3. Seven Additional Cases and the Birth of a Paper
Based on this observation, Dr. Alpan and colleagues reported in a paper published in 2025 that dupilumab showed improvement in FPIES symptoms in seven additional patients ranging from age 2 to 58 (the paper link is in the thread).
While not yet definitive evidence, the paper suggests that dupilumab could be a treatment candidate for FPIES. The research team announced plans to contact the drug manufacturer Regeneron to apply for clinical trials and FDA approval based on this data.
"These results are not definitive evidence, but they suggest that dupilumab could be a potential treatment for FPIES."
4. GPT-5 Pro's Independent Treatment Suggestion
Around the time the paper was submitted, Dr. Unutmaz heard this remarkable story and decided to test the newly released GPT-5 Pro by presenting it with the same clinical case to see if it could reason toward a treatment. After watching the AI's thinking process for about 12 minutes with great anticipation, a stunning result emerged.
"GPT-5 Pro's first recommendation was 'dupilumab (IL-4R-alpha blocker).' I was truly astonished at that moment!"
The AI demonstrated the insight that dupilumab, used for skin conditions, could also apply to FPIES treatment based on its "broader epithelial effects." Most other models did not rank this drug as their top choice, and even GPT-5 Thinking only suggested it as a second or third option.
Additionally, GPT-5 Pro clearly flagged warnings about existing symptomatic treatment drugs that carried high side-effect risks or had limited effectiveness.
5. AI and the Future of Medical Innovation
Dr. Unutmaz predicted that applications like this could expand the possibilities of drug repurposing for diseases that currently have no treatments. He emphasized that among the more than 20,000 FDA-approved drugs, AI could find combinations that humans hadn't considered, accelerating medical progress.
"I'm incredibly excited about what AI, and even more powerful AI in the future, will create in terms of innovation!"
However, he clearly stated that the full process of clinical trials and regulatory approval must still be followed.
6. Safety Notice and Research Ethics
Finally, dupilumab has not yet been approved by the U.S. FDA for the treatment of FPIES. The patients in this study were those with other FDA-approved allergic conditions where FPIES responses were incidentally observed.
"This is not medical advice, and patients should not start or stop drug treatments without consulting their physician."
He also disclosed that the GPT-5 Pro results were shared with colleagues before the paper was published.
In Closing
An era is dawning in which AI, particularly advanced models like GPT-5 Pro, can have a real impact on clinical decisions. This case -- combining a single patient's serendipitous experience, AI's insight, and rapid clinical validation -- strongly suggests that the trend of drug repurposing and AI's role in medical innovation will continue to expand. However, it's essential to remember that safety, clinical evidence, and patient-physician communication remain the most important values.